Eton Pharmaceuticals (ETON) Common Equity (2017 - 2026)

Eton Pharmaceuticals has disclosed Common Equity across 10 years of filings, most recently posting $46.6 million for Q2 2026.

• In Q2 2026, Common Equity rose 94.42% year-over-year to $46.6 million; the TTM figure through Jun 2026 stood at $46.6 million (up 94.42% YoY), while the FY2025 annual figure was $26.2 million, up 7.07% from the prior year.
• Common Equity came in at $46.6 million for Q2 2026 at Eton Pharmaceuticals, up from $26.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $50.0 million in Q3 2023 to a low of $11.2 million in Q3 2022.
• Average Common Equity over 5 years is $21.1 million, with a median of $16.0 million recorded in 2024.
• Year-over-year, Common Equity surged 347.19% in 2023 and plunged 68.04% in 2024.
• Over 5 years, Common Equity stood at $13.1 million in 2022, then rose by 18.34% to $15.5 million in 2023, then soared by 57.83% to $24.4 million in 2024, then climbed by 7.07% to $26.2 million in 2025, then soared by 78.12% to $46.6 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $46.6 million in Q2 2026, $26.2 million in Q4 2025, and $23.1 million in Q3 2025.